EXAS
Price
$53.57
Change
-$0.11 (-0.20%)
Updated
Sep 26 closing price
Capitalization
10.14B
31 days until earnings call
SARTF
Price
$201.69
Change
+$13.81 (+7.35%)
Updated
Sep 23 closing price
Capitalization
14.2B
Interact to see
Advertisement

EXAS vs SARTF

Header iconEXAS vs SARTF Comparison
Open Charts EXAS vs SARTFBanner chart's image
Exact Sciences
Price$53.57
Change-$0.11 (-0.20%)
Volume$2.25M
Capitalization10.14B
Sartorius AG
Price$201.69
Change+$13.81 (+7.35%)
Volume$10
Capitalization14.2B
EXAS vs SARTF Comparison Chart in %
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SARTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. SARTF commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a Buy and SARTF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (EXAS: $53.57 vs. SARTF: $201.68)
Brand notoriety: EXAS: Notable vs. SARTF: Not notable
EXAS represents the Medical Specialties, while SARTF is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EXAS: 70% vs. SARTF: 86%
Market capitalization -- EXAS: $10.14B vs. SARTF: $14.2B
EXAS [@Medical Specialties] is valued at $10.14B. SARTF’s [@Pharmaceuticals: Other] market capitalization is $14.2B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $158.13B to $0. The average market capitalization across the [@Medical Specialties] industry is $10.5B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileSARTF’s FA Score has 0 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • SARTF’s FA Score: 0 green, 5 red.
According to our system of comparison, EXAS is a better buy in the long-term than SARTF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 5 TA indicator(s) are bullish while SARTF’s TA Score has 3 bullish TA indicator(s).

  • EXAS’s TA Score: 5 bullish, 5 bearish.
  • SARTF’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, EXAS is a better buy in the short-term than SARTF.

Price Growth

EXAS (@Medical Specialties) experienced а +0.47% price change this week, while SARTF (@Pharmaceuticals: Other) price change was +7.35% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.53%. For the same industry, the average monthly price growth was +4.90%, and the average quarterly price growth was +24.99%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.13%. For the same industry, the average monthly price growth was -3.06%, and the average quarterly price growth was +8.48%.

Reported Earning Dates

EXAS is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Medical Specialties (+1.53% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Pharmaceuticals: Other (-1.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SARTF($14.2B) has a higher market cap than EXAS($10.1B). SARTF YTD gains are higher at: 9.611 vs. EXAS (-4.663). SARTF has higher annual earnings (EBITDA): 844M vs. EXAS (-758.48M). SARTF (872M) and EXAS (858M) have equal amount of cash in the bank . EXAS has less debt than SARTF: EXAS (2.52B) vs SARTF (4.66B). SARTF has higher revenues than EXAS: SARTF (3.47B) vs EXAS (2.94B).
EXASSARTFEXAS / SARTF
Capitalization10.1B14.2B71%
EBITDA-758.48M844M-90%
Gain YTD-4.6639.611-49%
P/E RatioN/A114.49-
Revenue2.94B3.47B85%
Total Cash858M872M98%
Total Debt2.52B4.66B54%
FUNDAMENTALS RATINGS
EXAS vs SARTF: Fundamental Ratings
EXAS
SARTF
OUTLOOK RATING
1..100
9250
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9787
PRICE GROWTH RATING
1..100
4952
P/E GROWTH RATING
1..100
10084
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (44) in the Biotechnology industry is somewhat better than the same rating for SARTF (79) in the null industry. This means that EXAS’s stock grew somewhat faster than SARTF’s over the last 12 months.

EXAS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SARTF (100) in the null industry. This means that EXAS’s stock grew similarly to SARTF’s over the last 12 months.

SARTF's SMR Rating (87) in the null industry is in the same range as EXAS (97) in the Biotechnology industry. This means that SARTF’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (49) in the Biotechnology industry is in the same range as SARTF (52) in the null industry. This means that EXAS’s stock grew similarly to SARTF’s over the last 12 months.

SARTF's P/E Growth Rating (84) in the null industry is in the same range as EXAS (100) in the Biotechnology industry. This means that SARTF’s stock grew similarly to EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASSARTF
RSI
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
43%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
70%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
52%
MACD
ODDS (%)
Bearish Trend 3 days ago
76%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
54%
Advances
ODDS (%)
Bullish Trend 4 days ago
71%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
81%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
56%
Aroon
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 5 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SARTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CCRN14.231.08
+8.21%
Cross Country Healthcare
SGLY1.090.02
+1.87%
Singularity Future Technology Ltd
SWKS79.510.15
+0.19%
Skyworks Solutions
VANI1.43N/A
N/A
Vivani Medical
NN15.73-0.16
-1.01%
NextNav

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with ILMN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then ILMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-0.20%
ILMN - EXAS
36%
Loosely correlated
-0.54%
RVTY - EXAS
34%
Loosely correlated
+1.23%
A - EXAS
34%
Loosely correlated
+1.23%
XRAY - EXAS
33%
Poorly correlated
+2.38%
VCYT - EXAS
32%
Poorly correlated
+1.89%
More

SARTF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SARTF has been loosely correlated with SDMHF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if SARTF jumps, then SDMHF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SARTF
1D Price
Change %
SARTF100%
N/A
SDMHF - SARTF
39%
Loosely correlated
-7.49%
SOAGY - SARTF
27%
Poorly correlated
+0.63%
EXAS - SARTF
21%
Poorly correlated
-0.20%
RSMDF - SARTF
16%
Poorly correlated
N/A
RYLPF - SARTF
9%
Poorly correlated
N/A
More